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Abstract
Background: Deep venous thrombosis (DVT) is an important complication in the peripartal and
postpartal period.
Methods: We followed up prospectively the prevalence of DVT in 34720 prenatal mothers
between June 2002 and July 2006 attending the antenatal clinics of two major hospitals in Mumbai,
India. Thirty two women (0.1%) presented for the first time with symptomatic DVT i.e. 17 in the
first trimester, 6 in the second and 9 in the third trimester of pregnancy. Nine had history of fetal
loss while in the remaining twenty three there was no history of fetal loss.
Results: The evaluation of both acquired and heritable thrombophilia showed a conglomeration
of thrombophilia in this group when compared to 100 normal pregnant women who have given
birth to at least one healthy baby with no history of fetal death, DVT or other obstetrical
complications. The relative risks for all the antiphospholipid antibodies (APA) studied i.e lupus
anticoagulant (LA), IgG/IgM antibodies for cardiolipin (ACA), β2 glycoprotein 1 (β2 GP 1) and
annexin V were significantly higher in women with pregnancy associated DVT (RR 7.4 95% CI 4.3–
11.3 P < 0.05). Among the genetic thrombophilia markers studied, Protein S (PS) deficiency was
the strongest risk factor (RR 5.00 95% CI 3.02–5.00 P < 0.05) followed by factor V Leiden (FVL)
mutation (RR 4.57 95% CI 2.23–4.57 P < 0.05) and PAI 4G/4G homozygosity (RR 3.24 95% CI 1.85–
5.12 P < 0.05). Protein C (PC) and endothelial protein C receptor (EPCR) 23 bp insertion
polymorphism was also increased in the patient group as compared to controls but the difference
was not statistically significant. The MTHFR C677T, fibrinogen gene β448 Arg/Lys polymorphisms
were not significantly different from the normal controls, while antithrombin III (AT III) deficiency
and PT G20210A polymorphism were absent in both controls and patients. Two or more risk
factors were present in 22 out of 32 cases (68.75%).
Conclusion: We conclude that the prevalence of DVT in India is more or less similar to other
reports published and both acquired and heritable thrombophilia show strong association with
DVT associated with pregnancy.
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The incidence of venous thrombosis in pregnant women
is approximately 1 in 1000 – 20000 pregnancies [1]. It is
an uncommon but the leading cause of mortality and
morbidity in antenatal women.
During normal pregnancy, a series of changes take place
in the coagulant and anti-coagulant pathways of blood
coagulation as well as in the fibrinolytic pathway [2,3].
The plasma concentration of several proteins and their
activities change and there is a hemostatic imbalance
towards a prothrombotic state. Placenta and myometrium
also contribute to a high concentration of a specific fibri-
nolytic inhibitor i.e PAI II during normal pregnancy [4].
In addition, the hormonal changes which occur during
pregnancy tilt the thrombohaemorrhagic balance towards
thrombosis to prevent severe postpartal blood loss. In
spite of all these changes postpartal venous thrombosis is
several times more common than antenatal venous
thrombosis [5,6].
The presence of thrombophilia is an added risk factor for
venous thromboembolism (VTE) during pregnancy.
Except one report on postpartal cerebral venous thrombo-
sis [7] there are no data on the prevalence of DVT during
pregnancy in India. Neither there are any data on the risk
assessment in women presenting with DVT for the first
time during pregnancy. The present study was thus aimed
at finding the prevalence and the risk associated with VTE
in antenatal mothers attending two of the largest hospitals
in Mumbai during the last four years.
Methods
Patients
The study was carried out between June 2002 and July
2006 on 34720 pregnant women attending the outpatient
Departments of Obstetrics & Gynaecology, KEM Hospital
and Nowrosjee Wadia Maternity Hospital, Mumbai,
India. Clinical examination for symptomatic DVT was car-
ried out by two Gynaecologists independently. DVT was
documented by venography, Doppler ultrasound angiog-
raphy, or MRI. None of the patients with confirmed DVT
were neither receiving any anticoagulant therapy at the
time of study. Only two patients had positive family his-
tory of DVT among first degree relatives.
Controls
One hundred unrelated age matched pregnant women
with the same ethnic background as that of the pregnant
women with DVT were selected as controls for this study.
Majority of them were Marathas while very few were Guja-
ratis, South Indians, Muslims and others, in both the
groups. The control group included more or less equal
numbers in the first second and third trimesters. None of
the controls had a previous history of miscarriage or preg-
nancy complications and had at least one healthy baby at
the time of this study. Women with endocrinological dys-
function, chromosomal abnormalities, autoimmune dis-
ease, liver dysfunction were excluded from both the
patient and control group.
None of the patients who had DVT and the controls had
any other confounding factors like smoking or history of
taking oral contraceptives.
The study was approved by the Institute Ethics Commit-
tee.
Methods
Blood was collected in 3.13% trisodium citrate (9:1 blood
to anticoagulant). The platelet poor plasma was separated
by centrifuging at 2000 g for 10 minutes at 4°C. The
plasma was aliquoted and stored at -70°C till tested. The
cell pellet was preserved at -20°C for DNA extraction.
Screening coagulation tests (PT, APTT, TT) and fibrinogen
assays were performed in a semi-automated coagulation
analyzer (ST ART, Diagnostica Stago, Asniers, France).
Plasma AT III was measured in a fully automated STA
coagulation analyzer (STA Compact, Diagnositica Stago,
France). ACLA (IgG, IgM), β2 GP1 (IgG/IgM), Annexin V
(IgG/IgM) antibodies were measured by ELISA using com-
mercial kits (Varelisa, Freiburg. Pharmacia). Protein C,
total protein S were also measured by ELISA [Diagnostica
Stago, Asniers, France]. The presence of lupus anticoagu-
lant was assessed according to the criteria of International
Society of Thrombosis & Hemostasis [8] by using screen-
ing and confirmatory reagents LA1 & LA2 (Dade Behring,
Marburg Germany), Kaolin clotting time and dilute PT
tests.
DNA was extracted as described earlier [9] from the cell
pellet. Factor V Leiden, PT gene, MTHFR, Fibrinogen gene,
EPCR and PAI 4G/5G polymorphisms were studied as
described in earlier reports [10-15] with or without spe-
cific restriction enzyme digestion.
The assays for all the APA were repeated at least once with
a minimum time interval of 3 months between the two
tests while the PC, PS and AT III tests were also repeated
again at least 3 months after the delivery and only the post
delivery results were considered.
Statistical analysis
Relative risks (RR), 95% CI and P values were estimated
separately for each parameter and for the total number of
samples using SPSS10 software.Page 2 of 5
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Thirty two out of 34720 women presented with DVT dur-
ing pregnancy giving a prevalence of 0.1% in this series.
Seventeen presented with DVT in the first trimester, six in
the second while 9 presented in the third trimester.
The sites of thrombosis among 32 women presented with
DVT are shown in table 1.
The majority of the patients (75%) had lower limb DVT
out of which 9 had history of fetal loss. Three women had
cortical venous thrombosis while two were cases of Budd
chiary syndrome. Retinal and renal vein thrombosis was
observed in one case each and one was a case of gangrene.
The prevalence of acquired and genetic thrombophilia is
shown in tables 2 &3.
The IgG and IgM antibodies for ACLA and β2GPI were
detected in 31.25% and 6.25% respectively while the
prevalence of LA and anti annexin antibodies was found
to be 12.5% and 15.63% respectively in the patients. In
case of controls the prevalence of APA antibodies was 1%
each for ACLA, β2GPI and annexin V while LA was not
detected in any of the controls. Overall, 37.5% of the
patients were found to be positive for any of the antiphos-
pholipid antibodies/LA as against 3% among the normal
pregnancy controls (RR 7.4 95% CI 4.3 – 11.3 P < 0.05).
Among the genetic thrombophilia markers, the hetero-
zygous carrier rate for factor V Leiden was 12.5% as
against 0% in controls (RR 4.57 95% CI 2.23–4.57 P <
0.05) while the frequency of EPCR and PAI 4G/4G
homozygous state were 3.13% (RR 2.0; 95% CI 0.3–3.8 P
NS) and 40.63 % (RR 3.2 ; 95% CI 1.8–5.1 P < 0.05),
respectively. No difference in the prevalence was obt-
served in case of MTHFR and fibrinogen gene polymor-
phisms between the controls and patients. Among the
natural anticoagulants, protein S deficiency was a signifi-
cant marker with 21.88% of the patients showing his defi-
ciency (RR 4.6; 95% CI 2.6 – 5.6 P < 0.05) while Protein
C deficiency was found to in one case (3.13%; RR 2.8 ;
95% CI 0.5–4.1 P NS). None of the cases and controls
showed the presence of AT III deficiency and PT G20210A
polymorphism.
Twenty two out of 32 (68.75%) patients showed the pres-
ence of two or more risk factors.
Discussion
Pregnancy associated thrombosis is not a new condition
as case reports of Phlegmasia Alba dolens (white leg of
pregnancy) and Phlegmasia Coerulea dolens (Blue leg of
pregnancy) can be found in text books of Obstetrics and
Gynaecology since more than 70 years. However with
introduction of more tests for thrombophilia markers and
the ability to assess the variable relative risks of thrombo-
sis associated with various thrombophilia markers along
with better understanding of thrombohaemorrhagic bal-
ance in different thrombotic conditions, the subject is
now being studied with renewed enthusiasm.
Maternal morbidity in India is quite high i.e around 4–5%
[16,17]. Though the major cause of maternal morbidity in
western countries is venous thromboembolism, in India
haemorrhage, sepsis, complications during delivery,
severe anaemia and toxaemia are the major causes of peri-
natal mortality [18,19]. Except one report on puerperial
cerebral venous thrombosis [7], there is no data on the
prevalence or the risk assessment for thrombosis during
pregnancy from India.
Previous studies from western literature have reported
incidence rates ranging from 18–95 events per 100000
women years during pregnancy [20-22]. The incidence in
the present study is more or less the same. Moreover, the
incidence of DVT in the present study is of symptomatic
DVT and thus the prevalence obtained in the present
study must be regarded as the minimum incidence rate.
All these women have been followed up until delivery and
those women who failed follow up have not been
included in the study.
Presence of acquired thrombophilia i.e ACLA, β2 GPI and
anti annexin V antibodies was observed in 37.5% of the
women with a first objectivity confirmed episode of DVT
Table 1: Sites of thrombosis in women with pregnancy associated DVT.
Site of thrombosis Number (%)
Lower limb DVT with fetal loss 09 (28.1)
without fetal loss 13 (40.6)
Pregnancy induced hypertension (PIH) + DVT 02 (6.25)
Cortical venous thrombosis 03 (9.3)
Budd Chiary syndrome 02 (6.25)
Gangrene 01 (3.1)
Retinal vascular obstruction 01 (3.1)
Infra renal segment thrombosis 01 (3.1)Page 3 of 5
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ative risk for women with APA was much higher in preg-
nant women with DVT than that found in the normal
control pregnant women.
Among the genetic thrombophilia, factor V Leiden muta-
tion has been found to be the strongest risk factor as has
been observed in several other studies [23-25]. The preva-
lence of factor V Leiden mutation in our general popula-
tion and in deep vein thrombosis cases has been reported
to be 2.3% and 2.6%, respectively [26]. In comparison,
the mutation seems to be a strong risk factor in pregnant
women presenting with DVT for the first time. The PT
gene G20210A polymorphism has not been found in our
control population or the disease groups thus is either
extremely rare or nonexistent. The MTHFR C677T, fibrin-
ogen β448 gene polymorphisms were not significantly
different between the patients and the controls. The fibri-
nolysis gene polymorphism i,e PAI 4G/5G insertion/dele-
tion – 675 bp upstream from the transcription start site
has been found to play a key role with regulation of fibri-
nolysis and a few studies have shown an increased preva-
lence of 4G/4G polymorphism in cases of RSA [27]. Even
in this study, 4G/4G homozygosity has been found to be
a strong risk factor for DVT in pregnancy. Among the
blood coagulation inhibitors i.e. PC, PS & ATIII defi-
ciency, PS deficiency has been found to be strongly asso-
ciated with DVT in pregnancy. PS deficiency has also been
strongly linked to late pregnancy loss in several studies
[28]. Another important information from this study is
the presence of two or more factors causing throm-
bophilia in 22 out of 32 patients studied. The effect of
pregnancy on some of the plasma factors like PC, PS and
AT III has been ruled out by repeating these assays again
at least 3 months after delivery.
In more than half of the women, DVT events occurred in
the first trimester of the pregnancy. Higher frequency of
DVT events has been reported during the first 15 weeks
gestation [28]. Higher frequency of thromboembolic
events in the first trimester of pregnancy provides an addi-
tional clue that when thromboprophylactic therapy has to
be initiated it should begin much earlier in the pregnancy.
In pregnant women the common site of thrombosis was
left leg. In a meta analysis published earlier it has been
reported that about 82% of the objectively diagnosed DVT
occurred in the left lower extremity. Though the exact
cause is not known, anatomic reasons have been postu-
lated [29,30].
What are the clinical implications of such a study? The
important question always raised is whether all women
with thrombophilia needs to be anticoagulated during
pregnany. Anticoagulation therapy is certainly effective in
reducing the incidence of adverse pregnancy outcomes in
Table 3: Genetic thrombophilia markers in patients and controls
Thrombophilia marker Patients (n = 32) Number positive (%) Controls (n = 100) Number positive 
(%)
RR (95% CI) P value
FVL Het 4 (12.5) 0 4.0 (1.8–4.5) 0.001
PT G20210A 0 0 - -
EPCR Hets 1 (3.13) 1 (1) 2.0 (0.3–3.8) 0.392
MTHFR homo 1 (3.13) 1 (1) 2.0 (0.3–3.8) 0.392
MTHFR hetero 6 (18.75) 12 (12) 1.46 (0.6–2.7) 0.333
Fib β448 homo 1(3.13) 1(1) 2.0 (0.3–3.8) 0.392
Fib β448 hetero 5 (15.63) 12 (12) 1.2 (0.5–2.5) 0.594
PAI 4G/4G 13 (40.63) 10 (10) 3.2 (1.8–5.1) 0
4G/5G 12 (37.5) 61 (61) 0.4 (0.2–0.8) 0.020
5G/5G 5 (15.63) 29 (29) 0.5 (0.2–1.1) 0.132
PC Def 1 (3.13) 0 2.8 (0.5–4.1) 0.223
P S Def 7 (21.88) 0 4.6 (2.6–5.6) 0
AT III Def 0 0 - -
Table 2: Prevalence of different antiphospholipid antibodies in pregnant women with DVT and normal pregnant controls
APA Patients (n = 32) Number positive 
(%)
Controls (n = 100) Number positive 
(%)
RR (95% CI) P value
LA 4 (12.5) 0 3.6 (1.6–4.5) 0.003
ACLA 10 (31.25) 1 (1) 4.5 (2.7–5.5) 0
β2 GP 1 2 (6.25) 1 (1) 2.1 (0.6–3.7) 0.22
Annexin V 5 (15.63) 1 (1) 3.8 (1.9–4.6) 0.003
LA/ACLA/β2 GP 1/Annexin V 12 (37.5) 3 (3) 7.4 (4.3–11.3) 0Page 4 of 5
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history of idiopathic fetal loss. But is it justified to antico-
agulate women with thrombophilia without any such
adverse events as there are quite a few women who are car-
riers of thrombophilia and have successful pregnancy out-
comes. Whether there should be an evaluation case by
case or whether tailored therapy should be advised for
specific thrombophilia need to be investigated. We still do
not understand in quantitative terms why different
thrombophilia markers have different impact in produc-
ing thrombosis. All these will remain as queries only until
there are large studies on different antithrombotic modal-
ities in prospective clinical trials.
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